Key Advantages


Our pipeline includes a CTLA-4 antibody at the advanced pre-clinical stage and we promote additional immune-therapy antibodies which are at an earlier pre-clinical stage:

Immune Oncology

Clinical Indications:
Metastatic melanoma

Immune Oncology

  • Higher certainty and fast antibody generation of targeted-specific antibodies
  • Selective blocking of a single target among a closely related group of targets, which allows:
    1. Specific and exclusive blocking of the ligand/receptor binding domain, ‎aiming to increase patient response rate ‎
    2. Eliminating binding of conflicting ligands/receptors such as inhibitory versus ‎activatory modulators typical to immune checkpoint functions
© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet